Screener
Immunome IMNM Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $582,693 | $653,482 |
| Prepaid expenses and other current assets | 11,616 | 7,295 |
| Total current assets | 594,309 | 660,777 |
| Property and equipment, net | 17,081 | 14,636 |
| Operating right-of-use assets | 2,828 | 2,978 |
Item 1. Financial Statements.
FAQ
- What is Immunome's cash & equivalents?
- Immunome (IMNM) reported cash & equivalents of $582.69M in Q1 2026.
- How has Immunome's cash & equivalents changed year-over-year?
- Immunome's cash & equivalents increased by 126.2% year-over-year, from $257.61M to $582.69M.
- What is the long-term trend for Immunome's cash & equivalents?
- Over 5 years (2020 to 2025), Immunome's cash & equivalents has grown at a 75.0% compound annual growth rate (CAGR), from $39.77M to $653.48M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Immunome's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude